Publication: Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
Loading...
Identifiers
Date
2017-08-22
Authors
Ríos-Tamayo, Rafael
Martín-García, Agustín
Alarcón-Payer, Carolina
Sánchez-Rodríguez, Dolores
de la Guardia, Ana María Del Valle Díaz
García Collado, Carlos Gustavo
Jiménez Morales, Alberto
Jurado Chacón, Manuel
Cabeza Barrera, José
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.
Description
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone
Drug Design
Humans
Immunologic Factors
Multiple Myeloma
Survival Rate
Thalidomide
Dexamethasone
Drug Design
Humans
Immunologic Factors
Multiple Myeloma
Survival Rate
Thalidomide
DeCS Terms
CIE Terms
Keywords
dexamethasone, multiple myeloma, pomalidomide, triplet therapy